Product logins

Find logins to all Clarivate products below.


Cardiac Rhythm Management Devices | Market Insights | US | 2023

The COVID-19 global pandemic has had a significant impact on the US CRM device market in the short term, resulting in lost procedure volumes; however, following a period of recovery, the market will grow slightly through 2031. Revenue growth will be driven by rising ICM and pulse generator envelope procedure volumes and the adoption of premium-priced innovative products, such as leadless pacemakers and S-ICDs, but this will be largely offset by relatively flat pulse generator sales and price erosion.

This Medtech 360 Report provides comprehensive data and analysis on the state of the US cardiac rhythm management device market from 2019 through 2031.

Related Medtech Insights Reports

Report
Cardiac Rhythm Management Devices – Market Insights – Japan
The Japanese CRM device market will grow over the forecast period. The introduction of novel products—such as the Aurora EV-ICD and dual-chamber leadless pacemakers—and favorable reimbursement…
Report
Cardiac Rhythm Management Devices – Market Insights – Asia Pacific (Supplemental)
The Asia Pacific CRM device market will experience modest growth over the forecast period, driven primarily by the increasing volume of ICM procedures and the adoption of premium-priced devices,…
Report
Cardiac Rhythm Management Devices – Market Insights – Europe (Supplemental)
The European CRM device market will continue to grow modestly over the forecast period, driven primarily by rising ICM procedure volumes, the introduction of dual-chamber leadless pacemakers, and…
Report
Cardiac Rhythm Management Devices – Market Insights – Europe
The European CRM device market will continue to grow modestly over the forecast period, driven primarily by rising ICM procedure volumes, the introduction of dual-chamber leadless pacemakers, and…
Report
Cardiac Rhythm Management Devices | Market Insights | Europe | 2024
The European CRM device market will continue to experience modest growth through 2032, primarily due to increasing adoption of premium-priced devices such as leadless pacemakers and S-ICDs…